Study design
ICH, heart failure
AMI, HEART FAILURE
We conducted a post-hoc analysis of the recently published EMMY trial.The EMMY trial was a 1:1 randomized, multicentric, investigator-initiated, double-blind, and placebo-controlled trial to investigate the potential effects of the SGLT2-I Empagliflozin 10 mg daily on structural (EDV, ESV) as well as functional (ejection fraction, E/E’) cardiac parameters and heart failure biomarkers (NTproBNP) in patients after AMI [The EMMY trial was approved by the relevant regulatory authorities, by the Ethics Committee of the Medical University of Graz, Austria (EK 29–179 ex 16/17; EudraCT 2016-004591-22) and registered on ClinicalTrials.gov (NCT03087773). The EMMY trial was fully conducted in conformity with the 1964 declaration of Helsinki and all subsequent revisions as well as in accordance with the guidelines laid down by the International Conference on Harmonization for Good Clinical Practice (ICH GCP E6 guidelines).